Expert Interview
Q2 #4: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Ticker(s): BIIB, ESAIYDr. Mark Harris MD
- Roughly how many patients do you treat with AD per year? PROBABLY IN THE RANGE OF 150-200 PATIENTS A YEAR IF NOT MORE
- Roughly how many times have you prescribed Leqembi? I have prescribed Leqembi for probably between 15-20 patients
- Are you able to discuss your thoughts on donanemab and the Phase III data? YES.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
